BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19
• 22
• 23
• 24
• 25
• 26
• 29
• 30
• 31

• 

  ALS

  BrainStorm Gears Up for Phase IIIb NurOwn Trial Amidst ALS Malaise

  After a long and challenging journey for its stem cell therapy NurOwn, BrainStorm Cell Therapeutics has aligned with the FDA on the parameters of a Phase IIIb ALS trial that is expected to begin by the end of 2024.

  July 22, 2024

   · 

  6 min read

   · 

  Heather McKenzie
• 

  Career Advice

  Career Support, Development Trump Pay, According to Recent Reports

  Career support is the No. 2 driver of employee engagement while learning and development is No. 3, according to a new Right Management report. A recent BioSpace survey supports those findings.

  July 22, 2024

   · 

  2 min read

   · 

  Angela Gabriel
• 

  Regulatory

  GSK Plots Blenrep’s Path Back to Market With EU Filing

  GSK is seeking to relaunch Blenrep after its market withdrawal in 2022. The pharma is eyeing a second-line niche for the antibody-drug conjugate in the treatment of relapsed or refractory multiple myeloma.

  July 22, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Diabetes

  Innovent’s Lilly-Partnered Type 2 Diabetes Drug Aces Phase III in China, Inches Closer to Approval

  Innovent Biologics’ dual GLP-1/glucagon receptor agonist mazdutide is also being developed for chronic weight management. China’s regulator accepted Innovent’s drug application for this indication in February 2024.

  July 22, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Weight loss

  5 Startups Looking to Compete in the Obesity Space

  With GLP-1 receptor agonists expected to dominate the weight loss market in the near term, several young companies are building on this mechanism, while others are taking a completely different approach.

  July 22, 2024

   · 

  5 min read

   · 

  Roxanne Nelson
• 

  GLP-1

  Beyond Weight Loss: Novo and Lilly Look to Expand Their GLP-1 Pipelines

  While type 2 diabetes and obesity are the primary conditions currently treated with blockbuster GLP-1 drugs, Novo Nordisk and Eli Lilly aim to enter additional markets.
  
  

  July 22, 2024

   · 

  4 min read

   · 

  Grant Playter
• 

  Regulatory

  Lilly Wins Chinese Approval for Tirzepatide in Obesity on Heels of Novo’s Semaglutide

  Eli Lilly’s tirzepatide, which has previously been approved in China for diabetes, can now also be used for chronic weight management in the world’s second most populated country.

  July 22, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Infectious disease

  SIGA, US Government Ink $113M Procurement Deal for Smallpox, Mpox Drug

  Oral doses of SIGA Technologies’ antiviral drug Tpoxx will help the U.S. maintain its reserves of the vaccine in preparation for future potential outbreaks, according to the company.

  July 22, 2024

   · 

  1 min read

   · 

  Tristan Manalac
• 

  FDA

  Samsung Bioepis Gets FDA Approval for Biosimilar to AstraZeneca’s Soliris

  The South Korean company’s Epysqli is now FDA-approved for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome in the U.S., having grabbed the lead in the Soliris biosimilar market in Europe.

  July 22, 2024

   · 

  1 min read

   · 

  Kate Goodwin
• Press Releases

  IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation Process

  July 22, 2024

   · 

  2 min read